MDxHealth Reports Strong FY25 Revenue Growth, Significant EBITDA Improvement, Reaffirms Robust 2026 Guidance
MDXH has more than doubled off its 52-week low of $1.35 on elevated volume (2.7× avg).
Summary
MDxHealth reported strong 20% revenue growth for FY25 and a 92% improvement in Adjusted EBITDA loss, while reaffirming its robust 2026 revenue guidance and a target of 10% Adjusted EBITDA margin by year-end.
Key Events · Earnings and Guidance · MDXH
-
Strong Full-Year 2025 Financial Results
MDxHealth reported full-year 2025 revenue of $107.9 million, a 20% increase over 2024, and fourth-quarter revenue of $29.5 million, up 19% year-over-year. This follows the preliminary revenue figures reported on 2026-01-12.
-
Significant Adjusted EBITDA Improvement
The company achieved a 92% improvement in Adjusted EBITDA for the full year 2025, reducing the loss to ($1.1) million compared to ($14.7) million in 2024, indicating strong progress towards profitability.
-
Robust 2026 Guidance Reaffirmed
MDxHealth maintained its previously issued 2026 revenue guidance of $137-140 million, representing 27-30% growth, and confirmed its view of driving progress toward a 10% Adjusted EBITDA margin exiting 2026.
-
Interim CFO Appointed
Ron Kalfus has been appointed interim Chief Financial Officer, effective February 26, 2026.
Analysis · MDXH · Industrial Applications And Services
MDxHealth SA reported strong financial results for the full year 2025, with revenue increasing 20% to $107.9 million. The company also demonstrated significant progress towards profitability, improving its Adjusted EBITDA loss by 92% to ($1.1) million for the full year. This positive momentum is reinforced by the reaffirmation of robust 2026 revenue guidance of $137-140 million, representing 27-30% growth, and a target of a 10% Adjusted EBITDA margin exiting 2026. While cash and cash equivalents decreased to $29.0 million, the improved operational performance and clear path to profitability outlined in the guidance are key positive signals for investors. The appointment of an interim CFO is a secondary development.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDXH was trading at $3.45 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $175.7M. The 52-week trading range was $1.35 to $5.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.